医学
贝里穆马布
硫唑嘌呤
环磷酰胺
狼疮性肾炎
安慰剂
霉酚酸酯
内科学
免疫学
皮肤病科
抗体
化疗
疾病
病理
替代医学
B细胞
B细胞激活因子
移植
作者
Richard Furie,Brad H. Rovin,Frédéric Houssiau,Ana Malvar,Y K Onno Teng,Gabriel Contreras,Zahir Amoura,Xueqing Yu,Chi-Chiu Mok,Mittermayer B. Santiago,Amit Saxena,Yulia Green,Beulah Ji,C. Kleoudis,Susan W. Burriss,Carly Barnett,David A. Roth
标识
DOI:10.1056/nejmoa2001180
摘要
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. METHODS: , and no use of rescue therapy). The time to a renal-related event or death was assessed. RESULTS: A total of 448 patients underwent randomization (224 to the belimumab group and 224 to the placebo group). At week 104, significantly more patients in the belimumab group than in the placebo group had a primary efficacy renal response (43% vs. 32%; odds ratio, 1.6; 95% confidence interval [CI], 1.0 to 2.3; P = 0.03) and a complete renal response (30% vs. 20%; odds ratio, 1.7; 95% CI, 1.1 to 2.7; P = 0.02). The risk of a renal-related event or death was lower among patients who received belimumab than among those who received placebo (hazard ratio, 0.51; 95% CI, 0.34 to 0.77; P = 0.001). The safety profile of belimumab was consistent with that in previous trials. CONCLUSIONS: In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone. (Funded by GlaxoSmithKline; BLISS-LN ClinicalTrials.gov number, NCT01639339.).
科研通智能强力驱动
Strongly Powered by AbleSci AI